STEPHANIE MCLAUGHLIN: Open Payments
NPI 1508447939 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,195 in 114 payments from 15 companies in 2025. Trend: 2023 $2,995 · 2024 $2,924 · 2025 $2,195
Food & beverage: $2,195
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $361 |
| ABBVIE INC. | 24 | $352 |
| Alkermes, Inc. | 12 | $292 |
| Neurocrine BioSciences, Inc. | 10 | $271 |
| Corium, LLC | 12 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 4 | $73 |
| Indivior Inc. | 2 | $67 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, Azstarys, TRINTELLIX, REXULTI, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
